European Innovation QuickFire Challenge

Johnson & Johnson Innovation Limited and Johnson & Johnson Innovation, JLABS have launched the European Innovation QuickFire Challenge. Innovators with ideas, technologies, and solutions that improve human healthcare and impact the European ecosystem can now apply for up to €100,000 in grants and one year of residency at an available JLABS location, including access to the global JLABS community. We encourage applications from companies working on all aspects of human healthcare, and have a particular interest in the following areas:
  • Pharmaceuticals Consumer products
  • Medical devices
  • Global public health
  • Health technologiesCross sector initiatives
The innovator with the best idea, technology, or solution that improves human healthcare and impacts the European ecosystem will receive:
  • Up to €100,000 in grants
  • One year of residency at an available JLABS location, including access to the global JLABS community
Deadline: 15 June 2018
Apply now:
http://jlabs.tv/europe
Winners Announced: 5. November 2018 at BIO - Europe Copenhagen

More News

GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)
GQ Bio is pioneering a high-capacity adenovirus (HCAd) gene therapy vector platform that addresses some of the big challenges in the gene therapy field. (Picture: GQ Bio)

Pacira BioSciences Acquires GQ Bio

HTGF portfolio company GQ Bio, pioneering a high-capacity adenovirus gene therapy vector platform, was acquired by Pacira BioSciences, Inc. Pacira, the industry leader in its ...

Read more …
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)
At its new premises in the tecHHub Hamburg, CrystalsFirst is significantly expanding its operations to foster greater synergy. (Picture: CrystalsFirst)

CrystalsFirst Scales Operations...

CrystalsFirst, a leading provider of advanced structural biology solutions and AI-driven drug discovery, is pleased to announce a multi-million-euro expansion of its laboratory infrastructure and ...

Read more …
medac has received FDA approval for treosulfan (Copyright Adobe Stock - Nicolas Hermbach)

Strategic cornerstone for medac: FDA approves treosulfan for alloHSCT

medac has received FDA approval for treosulfan as a new drug application with orphan drug designation prior to allogeneic hematopoietic stem cell transplantation (alloHSCT) in ...

Read more …